Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug;93(7):e54.
doi: 10.1097/MD.0000000000000054.

Crohn's disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature

Affiliations
Review

Crohn's disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature

Mitsuro Chiba et al. Medicine (Baltimore). 2014 Aug.

Abstract

There is limited information in the use of antitumor necrosis factor α, infliximab, in patients on hemodialysis. In Crohn's disease (CD), only 3 cases are reported.A 76-year-old man on hemodialysis for renal failure caused by immunoglobulin A nephropathy developed diarrhea and abdominal pains. A marked edema was observed in the pretibia and ankle. An increase of C-reactive protein (CRP) and erythrocyte sedimentation rate, hypoalbuminemia, hypocholesterolemia, and moderate anemia was found. Ultrasonography and computed tomography (CT) found wall thickness in the left colon. Sigmoidoscopy revealed multiple ulcers in the sigmoid colon and noncaseating epithelioid granuloma was found in the biopsy specimen. Barium enema study exhibited collar button signs and longitudinal ulcers in the left colon.A severe form of CD was diagnosed. Metronidazole seemed to decrease CRP but was ineffective in ameliorating diarrhea. Infliximab rather than steroid hormone was chosen for the treatment. Standard induction therapy with infliximab was initiated. Symptoms rapidly improved then disappeared. CD activity index decreased from 747 to a remission level of 134 after 2 infusions of infliximab. Scheduled maintenance infliximab therapy was administered after the induction therapy. Ultrasonography and CT showed a disappearance of the wall thickness of the colon. Adverse reactions were not observed.Infliximab was effective and safe in a patient with CD on hemodialysis. Our case has added additional literature in accordance with previous reports supporting infliximab as effective and safe in patients on hemodialysis.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Clinical course. CRP (normal range ≤0.19 mg/dL); ESR (≤10 mm/h); fecal occult blood (<100 ng/mL); T chol (≥120 to ≤220 mg/dL). CDAI = Crohn’s disease activity index; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; IFX = infliximab; T chol = total cholesterol.
FIGURE 2
FIGURE 2
Endoscopic pictures of sigmoidoscopy. Inflamed mucosa with (A) multiple irregular-shaped ulcers (arrow) and (B) punched-out ulcer (arrow) was observed in the sigmoid colon.
FIGURE 3
FIGURE 3
Radiograph of barium enema study. Clear collar button signs were observed in the (A) sigmoid colon (arrows) and the (B) descending colon (short arrows). Long fine arrows in (B) show calcification of the aorta.

Similar articles

Cited by

References

    1. Karampetsou MP, Liossis SN, Sfikakis PP. TNF-α antagonists beyond approved indications: stories of success and prospects for future. QJM. 2010;103:917–928. - PubMed
    1. Tokayer AZ, Brandt LJ. Idiopathic inflammatory bowel diseases in the elderly. In: Inflammatory Bowel Disease. Philadelphia, PA: W.B. Saunders; 2000:335–341.
    1. Lichtenstein GR, Hanauer SB, Sandborn WJ. The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–483. - PubMed
    1. Chiba M, Sugawara T, Tsuda H, et al. Esophageal ulcer of Crohn’s disease: disappearance in 1 week with infliximab. Inflamm Bowel Dis. 2009;15:1121–1122. - PubMed
    1. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001;135:27–31. - PubMed

Substances